Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Army
Fish and Richardson
Novartis
McKinsey
Covington
Moodys
Federal Trade Commission
Dow
Accenture

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,613,949

« Back to Dashboard

Which drugs does patent 8,613,949 protect, and when does it expire?

Patent 8,613,949 protects TEKAMLO and is included in one NDA.

This patent has twenty-two patent family members in twenty countries.
Summary for Patent: 8,613,949
Title:Galenical formulations of organic compounds
Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Amlodipine, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50% or more after 20 minutes, and 70% or more after 30 minutes at pH 2, said pharmaceutical oral fixed dose combination being bioequivalent, or close to reaching bioequivalence, to a free dose combination of Aliskiren and Amlodipine.
Inventor(s): Valazza; Stephen (Matawan, NJ), Wagner; Robert F (Hillsborough, NJ), Vippagunta; Sudha (Morris Plains, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:13/063,955
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,613,949

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-001 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-002 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-003 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis TEKAMLO aliskiren hemifumarate; amlodipine besylate TABLET;ORAL 022545-004 Aug 26, 2010 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,613,949

PCT Information
PCT FiledSeptember 22, 2009PCT Application Number:PCT/US2009/057750
PCT Publication Date:March 25, 2010PCT Publication Number: WO2010/033954

International Patents Family Members for US Patent 8,613,949

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Tunisia 2011000100 ➤ Subscribe
Russian Federation 2014140552 ➤ Subscribe
Russian Federation 2011115712 ➤ Subscribe
Peru 02932011 ➤ Subscribe
Malaysia 153610 ➤ Subscribe
Mexico 2011002988 ➤ Subscribe
Morocco 32719 ➤ Subscribe
South Korea 20110060942 ➤ Subscribe
Japan 2015091830 ➤ Subscribe
Japan 2012503020 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Harvard Business School
Chinese Patent Office
Johnson and Johnson
Accenture
AstraZeneca
QuintilesIMS
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot